Genmab A/S (OTCMKTS:GNMSF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Genmab A/S (GNMSF) remained flat at $218.00 during trading on Friday. The stock had a trading volume of 198 shares. Genmab A/S has a 52-week low of $158.25 and a 52-week high of $225.50. The stock’s 50 day moving average is $218.51 and its 200-day moving average is $204.01. The company has a market capitalization of $13.24 billion, a P/E ratio of 70.16 and a beta of 1.08.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at

Get a free copy of the Zacks research report on Genmab A/S (GNMSF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.